Proton therapy

RayStation selected by more than 100 ion therapy clinics worldwide

Retrieved on: 
Wednesday, April 5, 2023

The latest of these customers is Moffitt Cancer Center in Florida, USA, who will add proton planning to their existing RayStation infrastructure, which has been in clinical use since 2019.

Key Points: 
  • The latest of these customers is Moffitt Cancer Center in Florida, USA, who will add proton planning to their existing RayStation infrastructure, which has been in clinical use since 2019.
  • The first ever customer for RayStation is WPE in Essen, Germany, who bought RayStation in 2009 for its proton clinic.
  • No other treatement planning system supports such a wide range of treatment techniques and delivery systems as RayStation does.
  • Today, we see that our efforts have paid off and that we with more than 100 clinics have about 80 per cent of the global market."

P-Cure Receives FDA Approval For Proton Therapy System For Treatment in Seated Position and Will Begin Treating Patients In Israel

Retrieved on: 
Monday, April 3, 2023

SHILAT, Israel, April 3, 2023 /PRNewswire-PRWeb/ -- P-Cure announced today clearance of its Adaptive Proton Therapy Solution by the FDA for sales in the USA.

Key Points: 
  • P-Cure, an Israel-based high-med-tech company, has developed affordable proton therapy technology for targeted treatment of cancer with significantly reduced treatment related side effects.
  • SHILAT, Israel, April 3, 2023 /PRNewswire-PRWeb/ -- P-Cure announced today clearance of its Adaptive Proton Therapy Solution by the FDA for sales in the USA.
  • P-Cure, an Israel-based high-med-tech company, has developed affordable proton therapy technology for targeted treatment of cancer with significantly reduced treatment related side effects.
  • Treatment of cancer with proton therapy is considered the gold standard for treating many types of cancer sites with unique clinical capabilities.

American Shared Hospital Services Reports Fourth Quarter and Year End 2022 Financial Results

Retrieved on: 
Friday, March 24, 2023

SAN FRANCISCO, CA, March 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the fourth quarter and twelve months ended December 31, 2022.

Key Points: 
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,161,000 for the fourth quarter of 2022, compared to $2,150,000 for the fourth quarter of 2021.
  • Net income attributable to American Shared Hospital Services was $1,328,000, or $0.21 per diluted share, compared to net income attributable to American Shared Hospital Services of $194,000, or $0.03 per diluted share, for 2021.
  • Net income attributable to American Shared Hospital Services in the fourth quarter 2022 was $246,000, or $0.04 per diluted share, compared to net income of $219,000, or $0.04 per diluted share, for the fourth quarter of 2021.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,161,000 for the fourth quarter of 2022, compared to $2,150,000 for the fourth quarter of 2021.

With Increase in Prostate Cancer, ProCure Doctors Urge Men Over 55 to Get Screened

Retrieved on: 
Monday, March 6, 2023

SOMERSET, N.J., March 6, 2023 /PRNewswire/ -- With data showing an increase in advanced prostate cancer cases, doctors at a leading New Jersey cancer treatment center urge men over 55 to get their annual screening.

Key Points: 
  • SOMERSET, N.J., March 6, 2023 /PRNewswire/ -- With data showing an increase in advanced prostate cancer cases, doctors at a leading New Jersey cancer treatment center urge men over 55 to get their annual screening.
  • However, after two decades of declines, the report also highlighted a 3 percent increase in the prostate cancer incidence rate each year from 2014-2019 – including a surge in late-stage cases.
  • Physicians at ProCure Proton Therapy Center suggest using the PSA (prostate specific antigen) screening test for men over the age of 55 who had an average risk for prostate cancer.
  • That is why we recommend that men over 55 have a conversation with their primary care doctor about getting screened annually."

Installation of Proton Therapy System Begins at Kansas City Proton Institute

Retrieved on: 
Tuesday, January 24, 2023

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the 15-ton compact accelerator for the MEVION S250i Proton Therapy System® was delivered on January 20, to Kansas City Proton Institute (KCPI).

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the 15-ton compact accelerator for the MEVION S250i Proton Therapy System® was delivered on January 20, to Kansas City Proton Institute (KCPI).
  • This milestone marks the beginning of the first true compact proton therapy system installation in Kansas City, and the fourth in the region.
  • Kansas City Proton Institute expects to begin treatments with the MEVION S250i system in Fall 2023 to treat all indications benefitting from the precision of proton therapy.
  • “The installation of Mevion’s cutting-edge proton therapy system is a giant step toward bringing the world’s most precise form of proton therapy to Kansas City and the Midwest region,” said Dr. Kenon Qamar, the lead radiation oncologist for Kansas City Proton Institute.

B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand

Retrieved on: 
Monday, February 13, 2023

TOKYO and BANGKOK, Feb. 13, 2023 /PRNewswire/ -- B dot Medical Inc. and Thammasat University, a leading national university in Thailand, have signed a memorandum of understanding to install the ultra-compact proton therapy system developed by B dot Medical. The agreement encourages installing the advanced cancer treatment system in Thailand, where the population profile is aging at the fastest pace among major ASEAN countries. The agreement provides B dot Medical an opportunity to expand proton therapy further in the global market.

Key Points: 
  • They will provide strong partnership for the business development of B dot Medical in Thailand and the ASEAN region.
  • B dot Medical's ultra-compact proton therapy system, one of the smallest in the world, is suitable for placement in such urban areas.
  • This breakthrough prompted Thammasat University to go forward with proton therapy.
  • The clinical trial required for the sale of a proton therapy system in Thailand will be led by Thammasat University.

Bracken Welcomes New Consultants Deepak Behera, MD, and Gitte Andreasen, Providing Expertise in Radiopharmaceuticals and Marketing, Respectively

Retrieved on: 
Wednesday, February 8, 2023

With the addition of these experts in their respective fields, the consulting group continues to leverage wisdom and collective expertise—advancing Bracken's intelligence ecosystem.

Key Points: 
  • With the addition of these experts in their respective fields, the consulting group continues to leverage wisdom and collective expertise—advancing Bracken's intelligence ecosystem.
  • Deepak is a highly accomplished nuclear medicine trained physician-scientist and executive with over 20 years of experience in nuclear medicine, specifically in clinical development, medical affairs, product launches, and radiopharmaceuticals.
  • He has an extensive background in the clinical, academic, and pharmaceutical/biotech sectors, has published more than 20 journal articles, and co-authored 2 patents.
  • Deepak's background as a nuclear medicine physician-scientist and industry executive offers exceptional deftness to his consulting work within the pharma/biotech/radiopharmaceutical industry.

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Retrieved on: 
Sunday, January 22, 2023

Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.

Key Points: 
  • Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.
  • * Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated.
  • The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million.
  • Improvement in precision imaging, surgery, and therapy are now essential to improving long term outcomes.

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Retrieved on: 
Sunday, January 22, 2023

Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.

Key Points: 
  • Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.
  • * Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated.
  • The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million.
  • Improvement in precision imaging, surgery, and therapy are now essential to improving long term outcomes.

Insights on the Proton Therapy Global Market to 2028 - Featuring Toshiba, Ion Beam Applications, Hitachi and Provision Healthcare Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The Global Proton Therapy Market size is expected to reach $963.6 million by 2028, rising at a market growth of 12.5% CAGR during the forecast period.

Key Points: 
  • The Global Proton Therapy Market size is expected to reach $963.6 million by 2028, rising at a market growth of 12.5% CAGR during the forecast period.
  • Proton radiation devices are used in proton therapy, sometimes referred to as proton radiotherapy and proton beam therapy.
  • In proton therapy, a beam of protons is directed towards the tumors using proton accelerators.
  • Equipment for proton therapy is expensive and takes up a lot of space.